Lacosamide for the treatment of epilepsy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 10, Issue 3, 2014, Pages 459-468

  De Biase, Stefano ^a,b   Gigli, Gian Luigi ^a,b   Valente, Mariarosaria ^a,b   Merlino, Giovanni ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Absorption; Distribution; Elimination; Lacosamide; Partial onset seizures; Pharmacokinetic; Status epilepticus; Toxicology

Indexed keywords

ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT; HARKOSERIDE;

CHEMISTRY; DRUG INTERACTION; DRUG SCREENING; EPILEPSY; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ACETAMIDES; ANTICONVULSANTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; EPILEPSY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84894164143     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2014.883378     Document Type: Article

References (65)

1. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg PsychiatrY 1996;61(5):433-43
2. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav 2008;12(4):540-6
3. Angus-Leppan H, Parsons LM. Epilepsy: Epidemiology, classification and natural history. Medicine 2008;36(11):571-8
4. Banerjee PN, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsya review. Epilepsy Res 2009;85(1):31-45
5. Shneker BF, Fountain NB. Epilepsy. Dis Mon 2003;49(7):426-78
6. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314-19
7. Hovinga CA. SPM-927. IDrugs 2003;6(5):479-85
8. French JA, White HS, Klitgaard H, et al. Development of new treatment approaches for epilepsy: Unmet needs and opportunities. Epilepsia 2013;54(Suppl 4):3-12
9. Weaver DF, Pohlmann-Eden B. Pharmacoresistant epilepsy: Unmet needs in solving the puzzle(s). Epilepsia 2013;54(Suppl 2):80-5
10. National Institute for Health and Clinical Excellence. CG137 epilepsy: NICE guideline 2012. Available from: Http://guidance.nice.org.uk/CG137/ NICEGuidance/pdf/English [Last accessed 22 December 2013]
11. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1261-73
12. European Medicines Agency. Lacosamide: Summary of product characteristics. Available from: Www.ema. europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000863/WC500050338.pdf [Last accessed 22 December 2013]
13. US FDA. Vimpat (lacosamide): Highlights of prescribing information. Available from: Www.accessdata.fda.gov/drugsatfda-docs/label/2013/022253s010, 022254s005,022255s002lbl. pdf [Last accessed 22 December 2013]
14. Bialer M. New antiepileptic drugs currently in clinical trials: Is there a strategy in their development? Ther Drug Monit 2002;24(1):85-90
15. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: A review of preclinical properties. CNS Drug Rev 2007;13(1):21-42 . Review that describes properties and features of LCM.
16. Stöhr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007;74(2-3):147-54
17. Horstmann R, Bonn R, Cawello W, et al. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia 2002;43(Suppl 7):188
18. Kellinghaus C. Lacosamide as treatment for partial epilepsy: Mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009;5:757-66 . Article that describes properties and features of LCM.
19. Wolff C, Carrington B, Varrin-Doyer M, et al. Drug binding assays do not reveal specific binding of lacosamide to collapsing response mediator protein 2 (CRMP-2). CNS Neurosci Ther 2012;18(6):493-500
20. Yoshimura T, Kawano Y, Arimura N, et al. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 2005;120(1):137-49
21. Czech T, Yang JW, Csaszar E, et al. Reduction of hippocampal collapsing response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem Res 2004;29(12):2189-96
22. Kropeit D, Schiltmeyer B, Cawello W, et al. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia 2004;45(Suppl 7):123-4
23. Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008;49(3):418-24. Trial that demonstrates safety and tolerability of intravenous LCM as replacement for oral LCM.
24. Bialer M, Johannessenb SI, Levyc RH, et al. Progress report on new antiepileptic drugs: A Summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83(1):1-43
25. Cawello W, Bökens H, Nickel B, et al. Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: Saliva as a surrogate of pharmacokinetics in the central compartment. Epilepsia 2013;54(1):81-8 . Trial that demonstrates bioequivalence of 200 mg LCM oral tablet and syrup formulation.
26. Doty P, Rudd GD, Stoehr T, et al. Lacosamide. Neurotherapeutics 2007;4(1):145-8
27. Cawello W, Kropeit D, Schiltmeyer B, et al. Food does not affect the pharmacokinetics of SPM 927. Epilepsia 2004;45(Suppl 7):307
28. Koo TS, Kim SJ, Ha DJ, et al. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats. Arch Pharm Res 2011;34(12):2059-64
29. Schiltmeyer B, Cawello W, Kropeit D, et al. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender. Epilepsia 2004;45(Suppl 7):313
30. Cross SA, Curran MP. Lacosamide: In partial-onset seizures. Drugs 2009;69(4):449-59
31. Greenaway C, Ratnaraj N, Sander JW, Patsalos PN. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 2011;52(2):258-63
32. Fountain N, Staelens L, Tytgat D, et al. Low lacosamide plasma protein binding in lacosamide-naive patients. Neurology 2012;78:P01.077
33. Thomas D, Scharfenecker U, Nickel B, et al. Low potential for drug-drug interaction of lacosamide. Epilepsia 2006;47(Suppl 4):200
34. Wang Y, Brittain JM, Wilson SM, et al. Emerging roles of collapsing response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. Commun Integr Biol 2010;3(2):172-5
35. Ben-Menachem E. Lacosamide: An investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today (Barc) 2008;44(1):35-40
36. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48(7):1308-17. Phase IIb trial that demonstrates efficacy and tolerability of LCM in the treatment of adults with uncontrolled partial-onset seizures.
37. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443-53. Phase III trial that demonstrates efficacy and tolerability of LCM in the treatment of adults with uncontrolled partial-onset seizures.
38. Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia 2010;51(6):958-67. Phase III trial that demonstrates efficacy and safety of LCM (400 and 600mg/day) as a adjunctive treatment in patients with uncontrolled partialonset seizures.
39. Schiltmeyer B, Thomas D, Horstmann R, et al. Lacosamide has no potential for interaction with metformin. Diabet Med 2006;23(Suppl 4):315-16
40. Stockis A, van Lier JJ, Cawello W, et al. Lack of effect of lacosamide in the pharmacokinetic and pharmacodynamic profiles of warfarin. Epilepsia 2013;54(7):1161-6
41. Cawello W, Rosenkranz B, Schmid B, et al. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and oral contraceptive. Epilepsia 2013;54(3):530-6
42. Husain A, Chung S, Faught E, et al. Long-term and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: Results from a Phase III open-label extension trial. Epilepsia 2012;53(3):521-8 . Trial that describes long-term efficacy and safety of LCM.
43. Rosenow F, Kelemen A, Ben-Menachem E, et al. Long-term adjunctive lacosamide in patients with uncontrolled partial-onset seizures: Results from the SP774 Phase III open-label extension trial. 29th International Epilepsy Congress; 28th August - 1st September 2011; Rome, Italy
44. Rosenfeld W, Fountain NB, Kaubrys G, et al. Lacosamide: Long-term safety and efficacy in partial-onset seizures. 29th International Epilepsy Congress; 28th August - 1st September 2011; Rome, Italy
45. Wehner T, Bauer S, Hamer HM, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009;16(3):423-5
46. Garcia-Morales I, Delgado RT, Falip M, et al. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures. Seizure 2011;20(10):801-4
47. Harden CL, Cohn A, Lowe M, et al. Initial post marketing experience with lacosamide in adult patients with epilepsy. Epilepsy Res 2012;98(2-3):260-3
48. EP2462990A1. European patent application. Available from: Http://patentimages.storage.googleapis.com/pdfs/43d1839757e9fdc60f9d/ EP2462990A1. pdf [Last accessed 22 December 2013]
49. Registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. Available from: Http://clinicaltrials.gov/[Last accessed 22 December 2013]
50. Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009;14:429-31
51. Goodwin H, Hinson HE, Shermock KM, et al. The use of lacosamide in refractory status epilepticus. Neurocrit Care 2011;14(3):348-53
52. Kellinghaus C, Berning S, Immisch I, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand 2011;123(2):137-41 . Article that describes LCM as a treatment option for the treatment of SE after failure of standard therapy or when standard agents are unsuitable.
53. Höfler J, Trinka E. Lacosamide as a new tratment option in status epilepticus. Epilepsia 2013;54(3):393-404. Review that describes the efficacy and safety of LCM in the treatment of SE.
54. Wasterlain C, Stçhr T, Mantagne A. The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus. Epilepsy Res 2011;94(1-2):10-17
55. Belcastro V, Vidale S, Pierguidi L, et al. Intravenous lacosamide as treatment option in post-stroke non convulsive status epilepticus in the elderly: A proofof- concept, observational study. Seizure 2013;22(10):905-7 . Article that exhibits safety and efficacy of LCM as a first-choice drug against post-stroke nonconvulsive SE.
56. Fountain NB, Krauss G, Isojarvi J, et al. Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partialonset seizures. Epilepsia 2013;54(1):58-65. Article that demonstrates the efficacy and tolerability of rapidly initiating adjunctive LCM via a single intravenous loading dose.
57. Guilhoto LMFF, Loddenkemper T, Gooty VD, et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011;44(6):414-19
58. Heyman E, Lahat E, Levin N, et al. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol 2012;16(1):15-19
59. Rastogi RG, Ng Y. Lacosamide in refractory mixed pediatric epilepsy: A prospective add-on study. J Child Neurol 2012;27(4):492-5
60. Sake J, Herbert D, Isojarvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010;24(12):1055-68
61. Villanueva V, Lopez-Gomariz E, Lopez-Trigo J, et al. Rational polytherapy with lacosamide in clinical practice results of a Spanish cohort analysis RELACOVA. Epilepsy Behav 2012;23(3):298-304
62. Zaccara G, Perucca P, Loiacono G, et al. The adverse event profile of lacosamide: A systematic review and meta-analysis of randomized controlled trials. Epilepsia 2013;54(1):66-74. A review and meta-analysis that describes the side effects of LCM.
63. Novy J, Patsalos PN, Sander JW, et al. Lacosamide neurotoxicity associated with concomitant use of sodium channelblocking antiepileptic drugs: A pharmacodynamic interaction? Epilepsy Behav 2011;20(1):20-3
64. Edwards HB, Cole AG, Griffiths AS, et al. Minimizing pharmacodynamic interactions of high doses of lacosamide. Acta Neurol Scand 2012;125(4):228-33
65. Krauss G, Ben-Menachem E, Mameniskiene R, et al. Intravenous lacosamide as short-term replacement for oral lacosamide in partial-onset seizures. Epilepsia 2010;51(6):951-7